Clinical trials: Libido Disorder
Sexual Dysfunctions, Psychological
Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder
The object of this trial is to assess the safety and efficacy of a 24 week course of flibanserin for the treatment of hypoactive sexual desire disorder in premenopausal women.
- Trial name
- NCT00996164
- Testing
- Flibanserin
- Where
- 75 sites in United States
- Volunteers
- 1,090 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Hypoactive Sexual Desire Disorder
Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women
This study is a randomized, double-blind, placebo-controlled, adaptive design, multi-center study of the long-term cardiovascular and breast safety of LibiGel in the treatment of HSDD in postmenopausal women with at least two…
- Trial name
- BLOOM (NCT00612742)
- Testing
- testosterone gel
- Where
- 149 sites in United States, Canada
- Volunteers
- 3,656 people
- Sponsor
- BioSante Pharmaceuticals
Menopause, Sleep Disturbance
Radicle Revive 24: A Study of Health and Wellness Products on Menopausal Health and Related Health Outcomes
A randomized, double-blind, placebo-controlled, direct-to-consumer trial assessing the impact of health and wellness products on hormonal health and associated health outcomes in women with menopausal health issues
- Conditions
- Menopause, Sleep Disturbance, Anxiety, Depression
- Trial name
- NCT06749288
- Testing
- Radicle Revive Active Study Product 4.1 Usage
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Radicle Science
Hypoactive Sexual Desire Disorder
Lybridos in Pre-and Postmenopausal Women With Hypoactive Sexual Desire Disorder
A double-blind, randomized, placebo-controlled, dose-finding study to investigate the safety and efficacy of Lybridos in the domestic setting in healthy female subjects with hypoactive sexual desire disorder and maladaptive…
- Trial name
- NCT02101203
- Testing
- 0.5 mgTestosterone + 10 mg Buspirone
- Where
- 10 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Emotional Brain NY Inc.
Female Sexual Interest/Arousal Disorder
Study to Evaluate the Effectiveness and Safety of Libicare® in Women With Low Arousal and Sexual Desire Levels
The purpose of this study is to evaluate the effectiveness of Libicare® in the sexual desire and arousal at 12 weeks in peri or postmenopausal women aged between 40 and 60 years old with low sexual desire and arousal compared…
- Trial name
- VITAL (NCT04188600)
- Testing
- Libicare, active control
- Where
- Spain
- Sponsor
- Procare Health Iberia S.L.
Hypoactive Sexual Desire Disorder
Lybrido for Female Sexual Dysfunction
The Lybrido study is a double-blind, randomized, placebo-controlled study with a 4-week baseline establishment period, 16 week treatment period and a follow up period for a total of 26 weeks on study.
- Trial name
- NCT01432665
- Testing
- Sildenafil, Testosterone
- Where
- 14 sites in United States
- Volunteers
- 196 people, healthy volunteers welcome
- Sponsor
- Emotional Brain NY Inc.
Sexual Dysfunctions, Psychological
Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America
The objective of this trial is to assess the safety and efficacy of 24-week course of flibanserin for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in naturally postmenopausal women.
- Trial name
- NCT01057901
- Testing
- Flibanserin
- Where
- 100 sites in United States, Canada
- Volunteers
- 748 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Hypoactive Sexual Desire Disorder (HSDD)
Study to Assess the Efficacy/Safety of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido
This study is designed to evaluate efficacy and safety of a testosterone patch as treatment for low libido in naturally menopausal women who are taking estrogen or estrogen/progestin therapy.
- Trial name
- NCT00349791
- Testing
- Testosterone Transdermal System
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 549 people
- Sponsor
- Warner Chilcott
Hypoactive Sexual Desire Disorder
A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)
The purpose of this study is to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women with Hypoactive Sexual Desire Disorder(with or without Decreased Arousal).
- Trial name
- NCT04943068
- Testing
- Bremelanotide
- Where
- South Korea
- Volunteers
- 193 people
- Sponsor
- Kwang Dong Pharmaceutical co., ltd.
Skin Ageing, Healthy Ageing
Effects of a Multi-Targeted Oral Supplement on Skin, Hair, Sleep, Energy, Cognition, Libido and Epigenetic Biological Clock Age
This study evaluated the effects of a daily oral supplement regimen (Advanced ID Brain, Heart and Eye Omega Gel Capsules taken with Advanced ID Longevity and Collagen Complex Powder) on measures of skin condition, hair, sleep…
- Conditions
- Skin Ageing, Healthy Ageing, Effect of Oral Nutritional Supplementation on Skin, Hair, Sleep, Energy, Cognition and Sexual Wellbeing in Healthy Adults, Longevity
- Trial name
- IDF-AID-1 (NCT07827651)
- Testing
- Advanced ID
- Where
- United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- IDI Skincare Limited
Hypoactive Sexual Desire Disorder
Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido
This study is designed to evaluate efficacy and safety of a testosterone patch as treatment for low libido in surgically menopausal women who are taking estrogen therapy.
- Trial name
- NCT00331123
- Testing
- Testosterone Transdermal System
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 562 people
- Sponsor
- Warner Chilcott
Hypogonadism
ESPRIT Study in Hypogonadal Men
Observational study with AndroGel®, Testosterone 1% gel therapy (ESPRIT) in hypogonadal men in the community over 6 months.
- Trial name
- NCT01143818
- Testing
- AndroGel (testosterone gel) 1%
- Where
- 331 sites in Canada, Croatia and 7 more
- Volunteers
- 1,053 people
- Sponsor
- Abbott
Hypoactive Sexual Desire Disorder(HSDD)
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BP101 in Healthy Volunteers
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BP101 in Healthy Volunteers.
- Trial name
- NCT03102489
- Testing
- BP101
- Where
- Russia
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Ivix LLX
Sexual Dysfunctions, Psychological, Depression
12 Week Safety Trial of Flibanserin in Depressed Women Taking an SSRI or SNRI With Decreased Sexual Desire and Distress
The current trial will explore the safety of flibanserin in combination with Selective Serotonin Reuptake Inhibitors or Norepinephrine Serotonin Reuptake Inhibitors in a representative population of women with depressive and…
- Trial name
- NCT01040208
- Testing
- flibanserin 50 mg to 100 mg qhs, flibanserin 100 mg qhs
- Where
- 42 sites in United States
- Volunteers
- 111 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Hypoactive Sexual Desire Disorder
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)
The objective of this study is to evaluate the persistence of benefit of LibiGel (testosterone gel) 300 mcg/day compared to placebo gel in a 12 week post-treatment period of Hypoactive Sexual Desire Disorder (HSDD) in surgically…
- Trial name
- NCT01235754
- Testing
- transdermal testosterone gel 1%
- Where
- 102 sites in United States, Canada
- Volunteers
- 626 people
- Sponsor
- BioSante Pharmaceuticals
Hypogonadism, Late Onset Hypogonadism
Study of DHT-Gel to Treat the Symptoms of Low Testosterone in Men 55-80
The purpose of this study is to evaluate whether DHT-Gel, when applied daily to the skin, can relieve the symptoms of low testosterone in men aged 55-80.
- Conditions
- Hypogonadism, Late Onset Hypogonadism, Low Testosterone
- Trial name
- NCT00163566
- Testing
- Dihydrotestosterone (0.7%) in hydroalcoholic gel
- Where
- 16 sites in United States
- Volunteers
- 128 people
- Sponsor
- ASCEND Therapeutics
Sexual Desire Disorder
An Exploratory Investigation to Identify if Dame Product's "DLM" Works to Improve Sexual Desire and Mood in Females
This is a single-group, non-randomized, non-controlled, open-label observational trial to study and evaluate the efficacy of a commercial dietary supplement, called "DLM" ("test product").
- Trial name
- NCT05130411
- Testing
- DLM - Test product
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Dame Products, Inc.
Sexual Dysfunction, Psychological
Zestra in Women With Mixed Sexual Dysfunction
The objective of this study is to evaluate the clinical efficacy and safety of Zestra(TM) in women with acquired mixed desire/interest/arousal/orgasm disorders under conditions of home usage.
- Trial name
- NCT00118495
- Testing
- Non-prescription Zestra(TM): patented formulation
- Where
- 13 sites in United States
- Volunteers
- 200 people
- Sponsor
- QualiLife Pharmaceuticals
Sexual Dysfunctions, Psychological
Flibanserin Evaluation Over 28 Additional Weeks in Hypoactive Sexual Desire Disorder
Safety profile of flibanserin over 28 additional weeks Distribution of preferred dose regimens
- Trial name
- NCT00601367
- Testing
- flibanserin flexible dose
- Where
- 68 sites in Austria, Belgium and 10 more
- Volunteers
- 480 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Hypoactive Sexual Desire Disorder (HSDD)
Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study
The primary objective is to confirm the efficacy of intravaginal prasterone (DHEA) on Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women.
- Trial name
- NCT03619005
- Testing
- Prasterone 6.5 mg (0.50%) Vaginal Insert
- Where
- 10 sites in United States
- Sponsor
- EndoCeutics Inc.